Literature DB >> 27087410

Effects of chronic treprostinil treatment on experimental right heart hypertrophy and failure.

Sofie Axelgaard1, Sarah Holmboe1, Steffen Ringgaard2, Thomas K Hillgaard1, Stine Andersen1, Mona S Hansen1, Asger Andersen1, Jens E Nielsen-Kudsk1.   

Abstract

BACKGROUND: Right heart function is an important predictor of morbidity and mortality in pulmonary arterial hypertension and many CHD. We investigated whether treatment with the prostacyclin analogue treprostinil could prevent pressure overload-induced right ventricular hypertrophy and failure.
METHODS: Male Wistar rats were randomised to severe pulmonary trunk banding with a 0.5-mm banding clip (n=41), moderate pulmonary trunk banding with a 0.6-mm banding clip (n=36), or sham procedure (n=10). The banded rats were randomised to 6 weeks of treatment with a moderate dose of treprostinil (300 ng/kg/minute), a high dose of treprostinil (900 ng/kg/minute), or vehicle.
RESULTS: Pulmonary trunk banding effectively induced hypertrophy, dilatation, and decreased right ventricular function. The severely banded animals presented with decompensated heart failure with extracardial manifestations. Treatment with treprostinil neither reduced right ventricular hypertrophy nor improved right ventricular function.
CONCLUSIONS: In the pulmonary trunk banding model of pressure overload-induced right ventricular hypertrophy and failure, moderate- and high-dose treatment with treprostinil did not improve right ventricular function neither in compensated nor in decompensated right heart failure.

Entities:  

Keywords:  Right ventricular dysfunction; prostacyclin; pulmonary hypertension

Mesh:

Substances:

Year:  2016        PMID: 27087410     DOI: 10.1017/S1047951116000160

Source DB:  PubMed          Journal:  Cardiol Young        ISSN: 1047-9511            Impact factor:   1.093


  4 in total

1.  Efficacy of treprostinil in the SU5416-hypoxia model of severe pulmonary arterial hypertension: haemodynamic benefits are not associated with improvements in arterial remodelling.

Authors:  Ketul R Chaudhary; Yupu Deng; Colin M Suen; Mohamad Taha; Thomas H Petersen; Shirley H J Mei; Duncan J Stewart
Journal:  Br J Pharmacol       Date:  2018-09-16       Impact factor: 8.739

2.  Levosimendan improves cardiac function and myocardial efficiency in rats with right ventricular failure.

Authors:  Mona S Hansen; Asger Andersen; Lars P Tolbod; Nils H Hansson; Roni Nielsen; Anton Vonk-Noordegraaf; Jens Erik Nielsen-Kudsk
Journal:  Pulm Circ       Date:  2017-11-03       Impact factor: 3.017

3.  Treatment With Treprostinil and Metformin Normalizes Hyperglycemia and Improves Cardiac Function in Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction.

Authors:  Longfei Wang; Gunner Halliday; Joshua R Huot; Taijyu Satoh; Jeffrey J Baust; Amanda Fisher; Todd Cook; Jian Hu; Theodore Avolio; Dmitry A Goncharov; Yang Bai; Rebecca R Vanderpool; Robert V Considine; Andrea Bonetto; Jiangning Tan; Timothy N Bachman; Andrea Sebastiani; Charles F McTiernan; Ana L Mora; Roberto F Machado; Elena A Goncharova; Mark T Gladwin; Yen-Chun Lai
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-04-09       Impact factor: 8.311

4.  Impact of chronic hypoxia on proximal pulmonary artery wave propagation and mechanical properties in rats.

Authors:  Junjing Su; Charmilie C Logan; Alun D Hughes; Kim H Parker; Niti M Dhutia; Carl Christian Danielsen; Ulf Simonsen
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-03-16       Impact factor: 4.733

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.